[1]徐英杰,李 巍.三阴性乳腺癌早期患者雄激素受体、Ki67、p53、表皮生长因子受体表达水平及其与临床病理特征关系研究[J].陕西医学杂志,2021,50(12):1594-1597.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.032]
　XU Yingjie,LI Wei.Expression levels of androgen receptor,Ki67,p53,epidermal growth factor receptor and their relationship with clinicopathological characteristics in early stage triple-negative breast cancer patients[J].,2021,50(12):1594-1597.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.032]
点击复制

三阴性乳腺癌早期患者雄激素受体、Ki67、p53、表皮生长因子受体表达水平及其与临床病理特征关系研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
50
期数:
2021年12期
页码:
1594-1597
栏目:
临床病理
出版日期:
2021-12-05

文章信息/Info

Title:
Expression levels of androgen receptor,Ki67,p53,epidermal growth factor receptor and their relationship with clinicopathological characteristics in early stage triple-negative breast cancer patients
作者:
徐英杰; 李 巍
(锦州医科大学,辽宁 锦州 121001)
Author(s):
XU Yingjie; LI Wei
(Jinzhou Medical University,Jinzhou 121001,China)
关键词:
三阴性乳腺癌;  雄激素受体;  Ki67;  表皮生长因子受体;  临床病理特征
Keywords:
Triple-negative breast cancer;  Androgen receptor;  Ki67;  Epidermal growth factor receptor;  Clinicopathological characteristics
分类号:
R 737.9
DOI:
DOI:10.3969/j.issn.1000-7377.2021.12.032
文献标志码:
A
摘要:
目的:研究三阴性乳腺癌(TNBC)早期患者雄激素受体(AR)、Ki67、p53、表皮生长因子受体(EGFR)表达水平及其与临床病理特征的关系。方法:选取经临床病理诊断确诊的TNBC早期患者80例作为TNBC组,同时选取非三阴性乳腺癌(NTNBC)早期患者80例作为NTNBC组。应用免疫组化方法检测两组患者AR、Ki67、p53、EGFR表达水平并进行比较。分析各指标表达情况与TNBC早期患者临床病理特征之间的关系。结果:TNBC组患者AR阳性表达率显著低于NTNBC组,Ki67、p53及EGFR阳性表达率显著高于NTNBC组(均P<0.05)。TNBC患者中,AR阳性表达患者中出现淋巴结转移的患者比例更低,Ki67阳性表达患者中组织学分级Ⅱ期的患者比例更高,p53阳性表达患者中出现脉管内浸润的比例更高,EGFR阳性表达患者中肿瘤直径≥2 cm和出现脉管内浸润的患者比例更高(均P<0.05)。结论:TNBC早期患者AR表达降低,Ki67、p53、EGFR表达增加,且各指标与TNBC早期患者临床病理特征间均存在一定相关关系。
Abstract:
Objective:To study the expression levels of androgen receptor(AR),Ki67,p53 and epidermal growth factor receptor(EGFR)and their relationship with clinicopathological characteristics in early stage triple-negative breast cancer(TNBC)patients.Methods:A total of 80 early TNBC patients diagnosed by clinical pathology were selected as the TNBC group,and 80 early patients with non-triple negative breast cancer(NTNBC)were selected as the NTNBC group.The expression levels of AR,Ki67,p53 and EGFR in the two groups were detected by immunohistochemical methods and compared.The relationship between the expression of above indicators and the clinicopathological characteristics of early TNBC patients was analyzed.Results:The positive expression rate of AR in the TNBC group was significantly lower than that in the NTNBC group,and the positive expression rates of Ki67,p53 and EGFR were significantly higher than those in the NTNBC group(all P<0.05).Among TNBC patients,the proportion of patients with lymph node metastasis in AR-positive patients was lower,the proportion of patients with histological grade Ⅱ was higher in Ki67-positive patients,and the proportion of patients with p53-positive expression was higher in intravascular infiltration,and the proportion of patients with tumor diameter ≥ 2 cm and intravascular infiltration were higher in EGFR-positive patients(all P<0.05).Conclusion:The expression of AR in early TNBC patients decreases,and the expression of Ki67,p53,and EGFR increase.There is a certain correlation between each indicators and the clinicopathological characteristics of early TNBC patients.

参考文献/References:

[1] 王 乐,孙校华,张美珍,等.2013—2018年浙江省城市癌症早诊早治项目筛查结果初步分析[J].中国肿瘤,2020,29(12):904-909.
[2] 王 青,李明珠,程文瑾,等.中国女性常见妇科恶性肿瘤认知度调查[J].中国妇产科临床杂志,2020,21(4):420-422.
[3] 焦得闯,朱久俊,乔江华,等.ER-/PR+浸润性乳腺癌发病及分子特征研究[J].中华肿瘤防治杂志,2019,26(19):1449-1454.
[4] 刘伟伟.ER、PR、HER2、Ki-67在合并2型糖尿病乳腺癌患者肿瘤组织中的表达及临床意义[J].中华肿瘤防治杂志,2016,23(1):26-27.
[5] 高建朝,张志生,张淑宇,等.ER-α30和ER-α36在乳腺癌组织的表达及意义[J].临床肿瘤学杂志,2020,25(3):230-234.
[6] 刘 静,陆德铭.108例三阴性乳腺癌临床特征分析[J].时珍国医国药,2017,28(1):130-132.
[7] 赵振慧,李 妍,刘 炜,等.新疆地区乳腺癌患者复发、转移灶与原发灶分子标志物表达差异及分子亚型转型[J].中华乳腺病杂志:电子版,2020,14(4):234-239.
[8] 杨文涛,步 宏.第5版WHO乳腺肿瘤分类解读[J].中华病理学杂志,2020(5):400-405.
[9] 唐 林,陈巍魏,管晓翔.AJCC第8版乳腺癌分期系统更新的解读[J].临床肿瘤学杂志,2017,22(11):1038-1040.
[10] 陈玮黎,薛晓红,李思雨,等.扶正祛邪方对三阴性乳腺癌术后复发转移及免疫功能的影响[J].陕西中医,2021,42(6):739-742.
[11] 董国雷,赵伟鹏,佟仲生.三阴性乳腺癌靶向治疗进展[J].中国肿瘤临床,2019,46(12):649-652.
[12] 周 洁,陈 萱,陈 钰,等.三阴性乳腺癌的治疗现状及进展[J].医学研究生学报,2018,31(8):853-858.
[13] 祝景伟,佟经伟,许培权.Hippo信号通路中TAZ、YAP在三阴性乳腺癌中的表达及意义[J].陕西医学杂志,2020,49(8):940-943,968.
[14] Gupta GK,Collier AL,Lee D,et al.Perspectives on triple-negative breast cancer:Current treatment strategies,unmet needs,and potential targets for future therapies[J].Cancers(Basel),2020,12(9):2392.
[15] 蒋威华,张明帅,李涌涛,等.三阴性乳腺癌PALB2与雄激素受体表达关系及临床意义[J].实用医学杂志,2017,33(9):1381-1384.
[16] 吴晶晶,张 妍,林 琳,等.ER和PR阴性乳腺癌雄激素受体与HER2表达相关性及其临床意义[J].中华肿瘤防治杂志,2016,23(23):1544-1549.
[17] 马少君,刘延梅,康晓丽,等.三阴性乳腺癌雄激素受体表达与X线和超声影像特征关系研究[J].陕西医学杂志,2020,49(12):1584-1588.
[18] Sporikova Z,Koudelakova V,Trojanec R,et al.Genetic markers in triple-negative breast cancer[J].Clin Breast Cancer,2018,18(5):e841-e850.
[19] Kumar P,Aggarwal R.An overview of triple-negative breast cancer[J].Arch Gynecol Obstet,2016,293(2):247-269.
[20] 李黎洪,陈智伟,陈 昱,等.三阴性乳腺癌组织中Stathmin、p53蛋白表达变化及意义[J].山东医药,2017,57(41):71-73.
[21] 向国敏,刘晓珍,牛 昀.雄激素受体和表皮生长因子受体在ER阴性PR阴性乳腺癌中的表达意义研究进展[J].中华病理学杂志,2018,47(3):226-229.

相似文献/References:

[1]苏 成,李 斌,王可为△.术前新辅助化疗对三阴性乳腺癌患者血清Ki67、PDL1表达的影响*[J].陕西医学杂志,2019,(12):1605.
　SU Cheng,LI Bin,WANG Kewei..Effects of preoperative neoadjuvant chemotherapy on serum Ki67 and PDL1 expression in patients with triple negative breast cancer[J].,2019,(12):1605.
[2]祝景伟,佟经伟,许培权△.Hippo信号通路中TAZ、YAP在三阴性乳腺癌中的表达及意义[J].陕西医学杂志,2020,49(8):940.[doi:DOI:10.3969/j.issn.1000-7377.2020.08.007]
　ZHU Jingwei,TONG Jingwei,XU Peiquan..Expression and significance of TAZ and YAP in Hippo signaling pathway in triple negative breast cancer[J].,2020,49(12):940.[doi:DOI:10.3969/j.issn.1000-7377.2020.08.007]
[3]李秀华,唐冬梅,朱丽萍,等.三阴性乳腺癌临床病理特征与基因分型研究[J].陕西医学杂志,2021,50(8):1015.[doi:DOI:10.3969/j.issn.1000-7377.2021.08.028]
　LI Xiuhua,TANG Dongmei,ZHU Liping,et al.Clinicopathological features and genotyping of triple negative breast cancer[J].,2021,50(12):1015.[doi:DOI:10.3969/j.issn.1000-7377.2021.08.028]
[4]马少君,刘延梅△,康晓丽,等.三阴性乳腺癌雄激素受体表达与X线和超声影像特征关系研究*[J].陕西医学杂志,2020,49(12):1584.[doi:DOI:10.3969/j.issn.1000-7377.2020.12.012]

备注/Memo

备注/Memo:
基金项目:辽宁省锦州市指导性科技计划项目(JZ2020B017)
更新日期/Last Update: 2021-12-07